Aceclofenac

Cat. No.: HY-B0634 Purity: 99.91%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Aceclofenac is an orally active nonsteroidal anti-inflammatory agent (NSAID), with analgesic and anti-inflammatory properties. Aceclofenac is used for the research of osteoarthritis, ankylosing spondylitis, rheumatoid arthritis.

For research use only. We do not sell to patients.

Aceclofenac Chemical Structure

CAS No. : 89796-99-6

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 55	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 55	In-stock	Estimated Time of Arrival: December 31
Solid
500 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
1 g	USD 60	In-stock	Estimated Time of Arrival: December 31
5 g	USD 86	In-stock	Estimated Time of Arrival: December 31
10 g		Get quote
50 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Aceclofenac:

Aceclofenac-d₄ Get quote
Aceclofenac (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

View All Isoforms

COX COX-1 COX-2 COX-3

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

COX-2

3 μM (IC₅₀)

COX-1

7.3 μM (IC₅₀)

In Vitro

Aceclofenac (1-30 μM; 72 hours) significantly decreases interleukin-6 production and fully blocks prostaglandin E₂ synthesis by IL-1β- or LPS-stimulated human chondrocytes^[1].
Aceclofenac inhibits COX-1 with IC₅₀ values superior to 100 μM, but decreases by 50% COX-2 activity at the concentration of 0.77 μM in the whole blood test^[1].
Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Aceclofenac exhibits C_max (4.59 μg/mL) following oral administration (rat 20 mg/kg)^[3].
Aceclofenac exhibits terminal elimination half-life (rat 3.24 h) due to high plasma clearance (rat 1.10 L/h/kg) following intravenous injection (rat 10 mg/kg)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats weighing 32-340 g^[3]
Dosage:	10 mg/kg for i.v., 20 mg/kg for p.o. (Pharmacokinetic Analysis)
Administration:	Oral administration and intravenous injection
Result:	T_1/2 (3.24 h), C_max (4.59 μg/mL for p.o.).

Clinical Trial

Molecular Weight

354.18

Formula

C₁₆H₁₃Cl₂NO₄

CAS No.

89796-99-6

Appearance

Solid

Color

White to off-white

SMILES

O=C(OCC(O)=O)CC1=CC=CC=C1NC2=C(Cl)C=CC=C2Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (282.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8234 mL	14.1171 mL	28.2342 mL
5 mM	0.5647 mL	2.8234 mL	5.6468 mL
10 mM	0.2823 mL	1.4117 mL	2.8234 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.91%

Select Batch:

Data Sheet (277 KB) SDS (393 KB)

COA (253 KB) LCMS (92 KB)

Handling Instructions (2659 KB)

References

[1]. Y Henrotin, et al. In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm Res. 2001 Aug;50(8):391-9. [Content Brief]

[2]. E Maneiro, et al. Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. J Rheumatol. 2001 Dec;28(12):2692-9. [Content Brief]

[3]. E Maneiro, et al. Keumhan Noh, et al. Absolute bioavailability and metabolism of aceclofenac in rats. Arch Pharm Res. 2015 Jan;38(1):68-72. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8234 mL	14.1171 mL	28.2342 mL	70.5856 mL
	5 mM	0.5647 mL	2.8234 mL	5.6468 mL	14.1171 mL
	10 mM	0.2823 mL	1.4117 mL	2.8234 mL	7.0586 mL
	15 mM	0.1882 mL	0.9411 mL	1.8823 mL	4.7057 mL
	20 mM	0.1412 mL	0.7059 mL	1.4117 mL	3.5293 mL
	25 mM	0.1129 mL	0.5647 mL	1.1294 mL	2.8234 mL
	30 mM	0.0941 mL	0.4706 mL	0.9411 mL	2.3529 mL
	40 mM	0.0706 mL	0.3529 mL	0.7059 mL	1.7646 mL
	50 mM	0.0565 mL	0.2823 mL	0.5647 mL	1.4117 mL
	60 mM	0.0471 mL	0.2353 mL	0.4706 mL	1.1764 mL
	80 mM	0.0353 mL	0.1765 mL	0.3529 mL	0.8823 mL
	100 mM	0.0282 mL	0.1412 mL	0.2823 mL	0.7059 mL

Aceclofenac Related Classifications

Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Aceclofenac89796-99-6COXCyclooxygenaserheumatoidarthritisosteoarthritisankylosingspondylitiscytokineanalgesicanti-inflammatoryInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks